Provenge® (sipuleucel-T)

Starts the Fight and Helps His
Immune System Sustain* It


PROVENGE is immunotherapy for asymptomatic
or minimally symptomatic metastatic castrate
resistant prostate cancer (mCRPC)

Learn More >

At the time of
metastatic diagnosis

of CRPC patients may be eligible
for PROVENGE2

Treat Early - make sure your patients
take advantage of the PROVENGE window

Learn More >
  • Enrollment
  • Benefit
    Verification
  • Treatment
    Scheduling
  • Apheresis
    Support
  • Infusion
  • Billing &
    Reimbursement

Dendreon ON Call – Supporting Your Practice and Your Patients

Personalized Support For Your PROVENGE Patients
Is Just A Call Away...We Have You Covered

Learn More >

Sustained Immune Response And Short Duration Of Treatment*


Learn More >